Chroma is pioneering the future of single-dose genomic medicines, harnessing epigenetics to unlock precise, predictable, and durable therapies.
Epigenetics is the endogenous cellular system that determines the identity and function of each cell by controlling expression patterns of all genes. Although every cell in an individual has the same genome, each has a vastly different morphology, function, and phenotype. This is possible because each cell type has a unique and durable gene expression pattern which is established and maintained by epigenetics. This elegant system regulates which genes are expressed without altering the DNA sequence by laying down epigenetic marks such as methyl groups on the DNA, making genes accessible or inaccessible for transcription.
Chroma is building on the pioneering work of our scientific founders to advance a new class of genomic medicines that can durably silence, activate, and regulate multiple genes simultaneously (multiplexing).
Chroma’s novel programmable epigenetic editors couple a DNA binding domain with a modular epigenetic effector domain to target genes and control chromatin conformation. The DNA binding domain specifically targets the gene (or genes) to be silenced or activated. The effector domains create specific and durable methylation patterns which control chromatic conformation and govern whether a gene is accessible or inaccessible for transcription. This efficiently and effectively mimics the cell’s innate mechanisms for controlling gene expression.
Our modular platform enables us to develop medicines that address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once.
The elegance and simplicity of using nature’s endogenous approach for regulating the genome enables an incredibly efficient, precise, and versatile platform. With this, our epigenetic editors have a fundamental mechanistic advantage by completely eliminating expression of the targeted gene. In contrast, current editing approaches indirectly regulate gene expression by cutting the DNA, activating unpredictable DNA repair pathways and potentially producing immunogenic truncated or mutant proteins. These advantages make Chroma’s epigenetic editors the modality of choice for regulating the genome.
Our technology opens the door to new therapeutic possibilities, including targets in regions of the genome that are not accessible with other approaches, offering hope and lifelong cures for patients suffering from serious illnesses.